ExodusPoint Capital Management’s Stoke Therapeutics STOK Stock Holding History

ExodusPoint Capital Management’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.24M	Buy	+129,660	New	+$4.16M	0.03%	552
2022 Q4	–	Sell	-15,702	Closed	-$202K	–	2108
2022 Q3	$202K	Buy	+15,702	New	+$250K	﹤0.01%	1637
2021 Q1	–	Sell	-4,944	Closed	-$306K	–	2583
2020 Q4	$306K	Buy	+4,944	New	+$227K	﹤0.01%	1532

Other funds holding STOK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ExodusPoint Capital Management's STOK Position: Q2 2026 in Review

ExodusPoint Capital Management opened a new position in Stoke Therapeutics (STOK) in Q2 2026: 129,660 shares worth $4.24M. The stake represents 0.03% of the portfolio and ranks #552 among its holdings. This is a return to the name: ExodusPoint Capital Management previously reported a position in STOK as recently as Q3 2022.

ExodusPoint Capital Management first reported a position in STOK in Q4 2020 and has held it in 3 quarters since. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

ExodusPoint Capital Management held 129,660 shares of Stoke Therapeutics worth $4.24M as of Q2 2026.
Stoke Therapeutics was a new ExodusPoint Capital Management position in Q2 2026.
Stoke Therapeutics made up 0.03% of ExodusPoint Capital Management's portfolio in Q2 2026, its #552 holding.
ExodusPoint Capital Management first reported a position in Stoke Therapeutics in Q4 2020 and has held it in 3 quarters since.
197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.